Press Room - Sanofi US News
WEB2 days ago · About Multiple Sclerosis Multiple sclerosis is a chronic, immune-mediated, neurodegenerative disease that results in accumulation of irreversible disabilities over time. The physical and cognitive disability impairments translate into gradual deterioration of health status and lower quality of life, impacting patients’ care and life expectancy.
Sanofi lifts lid on data behind tolebrutinib’s mixed MS studies
WEB2 days ago · Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate tolebrutinib, linking the BTK inhibitor to a 31% delay in time to onset of ...
Sanofi eyes approval after MS therapy slows disease progression …
WEB2 days ago · Sanofi is eyeing global regulatory approval for tolebrutinib after releasing positive Phase III data in non-relapsing secondary progressive multiple sclerosis (MS),. The results from the HERCULES Phase III trial (NCT04411641) showed that Bruton tyrosine kinase (BTK) inhibitor delayed the time to six-month disability progression by 31% compared to placebo.
Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression
WEB2 days ago · September 20, 2024 at 5:30 AM EDT. Save. Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom ...
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
WEB2 days ago · SNY. By Ludwig Burger. FRANKFURT (Reuters) -Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French ...
Multiple sclerosis pill succeeds in key trial, Sanofi says - STAT
WEBSep 2, 2024 · Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies,...
Sanofi presents new data from robust MS clinical pipeline …
WEBOct 2, 2006 · Sanofi will present new data at the 9 th Joint ECTRIMS-ACTRIMS meeting evaluating three investigational treatments for multiple sclerosis (MS) that target the underlying biology of MS to treat the full spectrum of disease and reinforce the commitment to address smoldering neuroinflammation, a key driver of disability progression.
Tolebrutinib clinical trial program update - Sanofi
WEBAug 8, 2022 · The relapsing MS trials in the tolebrutinib clinical trial program, GEMINI I and GEMINI II, are now fully enrolled. Regulatory timelines for this indication remain unchanged with submission in relapsing MS expected in 2024.
Sanofi's Tolebrutinib Delays Disability Progression In Patients With ...
WEB2 days ago · Friday, Sanofi SA (NASDAQ:SNY) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive multiple sclerosis (nrSPMS). The data demonstrated that ...
BTK Inhibitor Tolebrutinib Slows Disability Progression in Phase 3 ...
WEBSep 3, 2024 · Tolebrutinib, a brain-penetrant BTK inhibitor, achieved the primary endpoint in the HERCULES study, significantly reducing disability accumulation in patients with non-relapsing secondary progressive multiple sclerosis. Houman Ashrafian, MD, PhD. Sanofi has announced topline data from its phase 3 HERCULES study (NCT04411641) of its ...
Skip to content